Under the accord, IDL will offer all of its early cancer tests, including ColonSentry, EarlyCDT-Lung, PHI and BreastSentry, as well as supportive tests, to physicians and patients via ALTN's 165 locations in the U.S.

"The agreement with ALTN very significantly expands our reach and, together with our existing clients, will allow us to offer our early cancer diagnostic tests throughout much of the U.S.," James Howard-Tripp, chairman and CEO of GeneNews, said in a statement.

"During April, we received over 3,000 requests for information, most of which were from physicians and patients, asking where they could gain access to our tests,” he added. “This partnership now allows us to link patients and physicians and give them immediate access to locations across the country where IDL testing can be initiated."

GeneNews expects the collection partnership activities to officially launch before the end of May.